Overview

Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC

Status:
NOT_YET_RECRUITING

Trial end date:
2028-05-30

Target enrollment:

Participant gender:

Summary

This is a multi-center, single-arm, phase II clinical study designed to observe and evaluate the effectiveness and safety of adebrelimab combined with albumin paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced resectable esophageal squamous cell carcinoma.

Phase:

PHASE2

Details

Lead Sponsor:

Harbin Medical University

Treatments:

Injections
nedaplatin